210 related articles for article (PubMed ID: 9359954)
21. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.
Navari R; Gandara D; Hesketh P; Hall S; Mailliard J; Ritter H; Friedman C; Fitts D
J Clin Oncol; 1995 May; 13(5):1242-8. PubMed ID: 7738628
[TBL] [Abstract][Full Text] [Related]
22. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy.
Italian Group for Antiemetic Research
N Engl J Med; 2000 May; 342(21):1554-9. PubMed ID: 10824073
[TBL] [Abstract][Full Text] [Related]
23. [Recent improvements in antiemetic therapy].
Roila F; Palladino MA; Ciccarese G; Basurto C
Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
[TBL] [Abstract][Full Text] [Related]
24. The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit.
Ng WL; Della-Fiorentina SA
Eur J Cancer Care (Engl); 2010 May; 19(3):403-7. PubMed ID: 19686353
[TBL] [Abstract][Full Text] [Related]
25. [Prophylaxis of chemotherapy-induced vomiting and nausea].
Tóth J; Szántó J
Magy Onkol; 2008 Dec; 52(4):391-4. PubMed ID: 19068468
[TBL] [Abstract][Full Text] [Related]
26. Patient outcomes after therapeutic interchange of dolasetron for granisetron.
Steiner MA; Yorgason RZ; Vermeulen LC; Theisen J
Am J Health Syst Pharm; 2003 May; 60(10):1023-8. PubMed ID: 12789874
[TBL] [Abstract][Full Text] [Related]
27. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
[TBL] [Abstract][Full Text] [Related]
28. Randomized, multicenter comparison of oral granisetron and oral ondansetron for emetogenic chemotherapy.
Herrington JD; Kwan P; Young RR; Lagow E; Lagrone L; Riggs MW
Pharmacotherapy; 2000 Nov; 20(11):1318-23. PubMed ID: 11079280
[TBL] [Abstract][Full Text] [Related]
29. Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy.
Gridelli C; Haiderali AM; Russo MW; Blackburn LM; Lykopoulos K
Support Care Cancer; 2010 Nov; 18(11):1437-44. PubMed ID: 19882176
[TBL] [Abstract][Full Text] [Related]
30. APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.
Schnadig ID; Agajanian R; Dakhil C; Gabrail NY; Smith RE; Taylor C; Wilks ST; Schwartzberg LS; Cooper W; Mosier MC; Payne JY; Klepper MJ; Vacirca JL
Future Oncol; 2016 Jun; 12(12):1469-81. PubMed ID: 26997579
[TBL] [Abstract][Full Text] [Related]
31. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
32. Progress in preventing chemotherapy-induced nausea and vomiting.
Markman M
Cleve Clin J Med; 2002 Aug; 69(8):609-10, 612, 615-7. PubMed ID: 12184469
[TBL] [Abstract][Full Text] [Related]
33. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
[TBL] [Abstract][Full Text] [Related]
34. Can granisetron injection used as primary prophylaxis improve the control of nausea and vomiting with low- emetogenic chemotherapy?
Keat CH; Phua G; Abdul Kassim MS; Poh WK; Sriraman M
Asian Pac J Cancer Prev; 2013; 14(1):469-73. PubMed ID: 23534775
[TBL] [Abstract][Full Text] [Related]
35. Are granisetron and ondansetron equivalent in the clinic?
Dilly S
Eur J Cancer; 1992; 28A Suppl 1():S32-5. PubMed ID: 1320918
[TBL] [Abstract][Full Text] [Related]
36. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.
Fox-Geiman MP; Fisher SG; Kiley K; Fletcher-Gonzalez D; Porter N; Stiff P
Biol Blood Marrow Transplant; 2001; 7(11):596-603. PubMed ID: 11760147
[TBL] [Abstract][Full Text] [Related]
37. Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin.
Oge A; Alkiş N; Oge O; Kartum A
J Chemother; 2000 Feb; 12(1):105-8. PubMed ID: 10768522
[TBL] [Abstract][Full Text] [Related]
38. Comparison of antiemetic efficacy of granisetron and ondansetron in Oriental patients: a randomized crossover study.
Poon RT; Chow LW
Br J Cancer; 1998 May; 77(10):1683-5. PubMed ID: 9635849
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
Oyama K; Fushida S; Kaji M; Takeda T; Yabushita K; Nezuka H; Kinami S; Kadoya N; Takai Y; Tsukioka Y; Ohyama S; Tsuji K; Tsukada T; Kinoshita J; Fujimura T; Ohta T
Int J Clin Oncol; 2016 Jun; 21(3):483-90. PubMed ID: 26507140
[TBL] [Abstract][Full Text] [Related]
40. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
Hsu ES
Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
